Mainz Biomed NV Investor Relations Material
Latest events
H2 2024
1 Apr, 2025
H1 2024
21 Oct, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Mainz Biomed NV
Access all reports
Mainz Biomed NV is a Germany-based molecular genetics diagnostic company focused on early detection of cancer. The company develops and commercializes in-vitro diagnostic tests, including non-invasive screening tools for colorectal cancer and other conditions. It operates in European and global markets with a focus on regulated clinical validation. The company is headquartered in Mainz, Germany, and its shares are listed on the NASDAQ.
Key slides for Mainz Biomed NV
H2 2024
Mainz Biomed NV
H2 2024
Mainz Biomed NV
Latest articles
)
MSCI: Indexing the World
The story of how MSCI has become the backbone of global finance through its indexes, powering decision-making across trillions in assets.
30 May 2025
)
A Purpose-Built AI Chat for Finance and IR Professionals
Quartr Pro's new AI chat lets IR and finance professionals ask anything across 13,000+ public companies and get instant answers.
27 May 2025
)
Costco Wholesale: The Model of Scalable Simplicity
Costco's rise from warehouse club to retail giant is built on low prices, scale efficiency, and a model designed for lasting customer value.
26 May 2025
Ticker symbol
MYNZ
Country
🇺🇸 United States